Oxaliplatin and fever: Report of 4 cases;Oxaliplatino y fiebre: presentación de 4 casos

Clinical and Translational Oncology

Volumn 3, Issue 3, 2001, Pages 155-158

  Salinas Hernández, Pedro ^a   Cortés Funes, Hernán ^a,b   Hitt Sabag, Ricardo ^a,b  

^a Clínica Oncocenter   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Colorectal cancer; Fever; Oxaliplatin

Indexed keywords

EID: 84873355209     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Culy Cr, Clemett D, Wiseman R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000; 60 (4): 895-924.
2. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647-662.
3. Ulrich-Pur H, Fiebiger WCC, Schüll B, et al. Oxaliplatininduced fever and release of IL-6. Oncology 2000; 59: 187-189.
4. Maindraut-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluoracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur J Cancer 1999; 35 (9): 1.338-1.342.
5. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high leucovorin and 5-fluoracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33 (2): 214-219.
6. Giacchetti S, Itzhaki M, Gruia G, et al. Supervivencia a largo plazo de los pacientes con metástasis hepáticas irresecables de cáncer colorrectal después de una quimioterapia con infusión de 5-fluoracilo, leucovorín, oxaliplatino y cirugía. Ann Oncol (ed esp) 1999; 8 (8): 881-887.
7. Wiseman LR, Adkins JC, Plosker GL, Goa KL. Oxaliplatin. A review of its use in the management of metastatic colorectal cancer. Drugs Aging 1999; 14 (6): 459-475.
8. Salinas P, Amador ML, Ciruelos E, et al. Analysis of biweekly oxaliplatin + folinic acid (FA) + 5-fluoracil (FU) in metastatic gastrointestinal carcinoma. Ann Oncol 2000; 11 (4 Supl): 50:217.
9. Medioni J, Coulon MA, Morere JF, et al. Anaphylaxis after oxaliplatin. Ann Oncol 1999; 10 (3): 610.
10. Rintala E, Pulkki K, Mertola J, et al. Endotoxin, interleukin - 6 and phospholipase A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995; 27 (1): 39-43.
11. Salinas P, Arias L, Terceño, Gandía I. Vías centrales de larga duración con reservorio subcutáneo. Experiencia en una Unidad de Oncología. Medicina Paliativa 1998; 5 (3): 136-140.
12. Carrato A, Barón JM, Díaz N. Complicaciones metabólicas en el enfermo con cáncer I: fiebre de origen tumoral. En: González Barón, Ordóñez, Feliú, Zamora, Espinosa, eds. Tratado de medicina paliativa. Madrid: Panamericana, 1996; 529-538.